OTC Observer Inc reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market

Sponsored Financial Content

Propanc Health Group Corp (OTCMKTS:PPCH) Heats up

Propanc Health Group Corp (OTCMKTS:PPCH) has seen a recent massive surge in trading volume coupled with a jump in share price resuming its place among the top most traded stocks on the entire bb exchange.
PPCH has runner in its blood initially exploding out of sub penny land running to an incredible $0.1338 a share. The run was sparked by an Investment Newsletter called the Wealthy Biotech Trader as well as a paid feature in the NY Times Sunday Edition Magazine under Health Essentials: Cancer Prevention & Treatment on April 19th.
Propanc Health Group Corp (OTCMKTS:PPCH) is focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with their scientific and oncology consultants, they have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body.
PPCH lead drug candidate, PRP, is a once-daily pro-enzyme treatment as a clinically proven therapeutic option in the treatment and prevention of cancer. PRP would be the first therapy of its kind, as there are no FDA approved therapies used for the long-term prevention or management of these conditions. Propanc is focusing on providing oncologists and their patients with more effective metastatic cancer therapies with a substantially reduced side effect profile; specifically, colorectal and pancreatic cancers. Improvement is needed for the standard of care for late stage cancer, with the incumbent treatments causing significant adverse effects for the modest benefits provided.
To Find out the inside Scoop on PPCH Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Back in May PPCH announced Game Changing News when they announced the first set of results from its series of animal studies, with PRP showing no adverse clinical signs at the maximum tolerated dose (MTD) in mice when administered by I.V injection. The MTD is more than twice the human equivalent dose administered to patients at the Dove Clinic for compassionate use.
Prior to the MTD mice study, the two proenzymes were individually assessed to measure activity in cell culture studies, with both active ingredients displaying inhibitory activity in pancreatic and ovarian cancer cell lines.
PPCH Chief Scientific Officer Dr Julian Kenyon said “These findings are significant, because it gives us confidence that PRP appears to be safe and tolerable when administered by I.V injection at higher doses. Furthermore, we can now presume one hundred percent of the drug has been absorbed into the bloodstream. This is not the case when I first treated patients with proenzymes with a suppository formulation at the Dove Clinic, which is expected to have a lower absorption rate.”
PPCH has some big names behind it; Klaus Kutz, CMO of Propanc has prepared multiple investigational new drugs (IND) FDA applications for Sanofi, a $48 stock. Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Novartis is now trading at $98 a share.
On November 10 PPCH announced it has secured $4 million from an institutional investor in order to progress their lead product, PRP, towards human trials.
Under the terms of the Agreement, a $1.2 million promissory note entered into by the investor on September 24th has now been included in the investment amount under the new purchase agreement. A further $2.8 million of the investment amount will be paid (totaling $4 million), pending the achievement of certain milestones and equity conditions set forth in the agreement.
The aggregate deal size provides sufficient capital to cover future research and development activities leading up to the preparation and commencement of human trials for their lead product, PRP, and is expected to sufficiently cover the Company’s operations over the next 12 months.

No comments:

Post a Comment